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Homeostasis in host immunity is the functional state that protects the body from disease while 
minimizing detrimental effects of an immune response, such as allergic, autoimmune or a 
suppressed immune response. As the normal human population's immunity can vary by more 
than two standard deviations [1–4], individuals can have wide fluctuations in how they express 
homeostasis. 
When these possible detrimental effects are considered, immunotoxicity or immune disorders 
can be divided into two categories: enhanced immunity (e.g., hypersensitivity, allergy, 
autoimmunity, sensitization and dermatitis) and suppressed immunity (e.g., hyposensitivity and 
immunosuppression), shown in Figure 1. Both categories represent an immune response that 
is unable to recognize self from nonself appropriately – presenting a risk such as an allergic 
response [1]. 
 
Figure 1. A model of immunomodulation in homeostasis. 
Exposure to an allergen 
Although the allergenicity of a substance-induced allergic response is highly subject-specific, a 
dose of allergen exceeding the threshold of a subject-specific level can cause an allergic 
response. Usually the dose is lower than a general toxicity level, but high enough to perturb 
the host immune system's homeostasis. This can occur through a single exposure or through 
multiple exposures. The first exposure might not cause any noticeable effects and some metal 
sensitizations can be triggered in humans by another metal, such as palladium cross reacting 
with nickel [5]. Once an allergen interacts with the individual, the immune system undergoes 
antigen processing to form a subject and allergen-specific hapten that can be processed and 
presented by antigen presenting cells. The response initiates an activation and maturation 
process, allowing the host immune system to memorize the ‘signature’, or the structured 
pattern, of the allergen complex. This first exposure can also adjust the threshold for a 
response. If a second exposure takes place, the immune system then quickly recognizes it as 
nonself and seeks to eliminate it in order to maintain the body's homeostasis. The protective 
action of the immune response is a double-edged sword; it removes the perceived threat, but it 
can result in damage to the host locally or systemically, ranging from pain to serious illness 
including death from anaphylaxis [1]. Here, we focus on metal and drug-associated allergic 
risks. 
Response to an allergen 
The response to an allergen is complicated as it depends on an individual's immune system. In 
other words, the same exposure could have diverse results in a population of individuals and 
an individual's response can change during a lifetime [6]. In contrast, general toxicity is a dose-
dependent event that shows relatively uniform manifestations from one individual to another. 
Allergic reactions are historically classified as type I, II, III and IV, but the mercury in dental 
amalgams can induce all types of allergic responses [7,8]. While nickel causes a type IV 
lymphocyte mediated delayed-type allergic response, it displays a common inflammatory 
morphological pattern, observed as a regional lymphocyte infiltration also seen in many other 
instances such a viral infection [9,10]. This challenges and confounds diagnostic and monitoring 
efforts that have an impact on clinical decision-making [11]. In the clinical setting, the 
manifestations usually do not show a clear cutoff between the different types of allergic 
responses, because the inflammatory response can be similar while the allergic response can 
be mixed [12–14]. We propose considering an additional category that is based on a substance 
classification, such as ‘metals’ to cover mercury and nickel allergies rather than a type based, 
to provide a clearer picture in clinical decision-making. 
Biomarkers are commonly used as diagnostic and monitoring tools that offer distinct 
advantages for improving clinical outcome [15]. Uncovering biomarkers to stratify the allergic 
risks and streamline clinical information can have a positive effect on medical interventions 
[16,17]. Ideally, physicians could then predict personalized risk prior to introduction of a metal-
containing medical device or a drug [17]. 
Current challenges & issues 
Stratification of categories associated with the allergens might result in a better understanding 
of the mechanisms behind the phenomena. Currently preclinical allergic risk assessments rely 
on animal-based tests [18]. However, this approach has been criticized for providing poor 
clinical relevance due to species variation in immune responses and drug metabolism [19–21]. 
Among animal species, nonhuman primates are considered the closest model for representing 
the human situation. However, sometimes human and nonhuman primates display a significant 
difference in their immune response, for example, their reaction to herpes simplex viral 
infection [4,20,22]. In drug-induced allergic responses, metabolites of a drug can also result in a 
specific allergic response in humans that is different from what is observed in nonprimate 
humans and can even be specific to an individual due to their unique forms of metabolic 
enzymes. Consequentially, the metabolite-hapten complex formation through human antigen 
presenting cells might also be unique. In devices that contain metals, nickel is a well-known 
human allergen with an allergic response prevalence estimated between 17 and 20% in the 
general population; but it is not an allergen in the mouse due to differences in Toll-like receptor 
4 [23–25]. 
Nickel, cobalt and chromium metals can leach out from alloy-based medical devices and ‘wear 
particles’ can form and increase with time from common daily activities. High concentrations of 
salts and amino acids along with mechanical loading, the interface between the device and the 
tissues, and the battery effects between dissimilar metals all promote metal ion release from a 
device. Patients who have allergic reactions commonly have high blood levels of metals [26]. 
Metal ions need to be conjugated with proteins to be recognized by a host immune system. In 
the case of nickel, the reconfirmation of endogenous proteins with nickel enlarges their size 
and the result can be allergenic [27,28]. However, these alloys must be used because they 
provide the mechanical strength necessary to support the body part, for example, the metallic 
hip joint supports the leg. Another concern is that computational modeling of structure–activity 
relationship and animal data do not discern between those who will get the product-related 
allergic response and those who will not [29,30], but both are somewhat informative for weighting 
risks and benefits. 
Because funding sources are more concerned with addressing major diseases than 
developing allergic biomarkers, the ones currently used in the clinics are considered obsolete 
[31]. As an alternative method, the human lymphocyte transformation test is considered as the 
secondary tier of tests for showing clinical relevance [32,33]. Recently, environmentally friendly 
lymphocyte transformation tests were developed using fluorescent probes and flow cytometry 
to eliminate the need of radioactive isotopes and to offer more precise information [34]. 
Commonly used animal-based testing models do not always predict the human outcome in a 
clinical study. This points out the importance of performing clinical trials [35], because some 
adverse events can only manifest from human biochemical and immunological reactions. For 
example, drugs repeatedly associated with autoimmune responses can cause drug-induced 
liver injury. Although only one out of 1000 to 10,000 humans experience drug-induced liver 
injury from resulting autoantibodies, irreversible liver failure is possible. Predicting which drugs 
will cause injury is an inexact science and monitoring alanine aminotransferase is an 
ineffective approach outside of clinical trials because it lacks specificity and sensitivity [36]. 
Allergic responses occur at a lower frequency in the clinic because they can take a long time to 
manifest; sometimes mild sickness and nondisease-specific symptoms of acute liver damage 
can take a few months or longer to develop after taking the medication. Without appropriate 
biomarkers, it is challenging to weight the risks and benefits accurately [37,38]. Thus, many case 
reports and adverse events were apparently overlooked due to the lack of availability of 
appropriate biomarkers [26] and it is estimated that allergic-related adverse events may have 
been under reported by as much as 90% [38]. 
Lack of communication can exist between the immunologists (allergist) and the surgeons or 
dentists who implant these metal containing devices and the physicians who prescribe the 
drugs. Even in the allergist setting, there is a lack of robust and reliable test methods. For 
example, skin patch and intradermal tests often show large numbers of false positives and 
negatives [39]. Once positive to an allergen such as nickel, the positivity will remain for a very 
long time and possibly for the individual's entire life, which does not reflect the clinical situation 
when the implant was removed and the symptoms no longer exist, but the test continues to 
remain positive [26]. Furthermore, these tests cannot differentiate between palladium cross-
reacting as nickel, because palladium has 90% cross reactivity with nickel [5]. 
In conclusion, to prevent allergic risks by capturing measurable signals of allergy in 
hypersensitive individuals and to improve diagnosing and monitoring patients’ health, clinically 
relevant, reliable and robust complementary biomarkers as a panel with validated sensitivity 
and specificity [36,40] need to be developed using relevant human material combined with 
individual-based in vitro test models to accurately predict the long-term clinical outcome [35,41]. 
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